Latest Capital Raising News

ECS Botanics has reported a return to profitability and positive cash flow in the first half of FY26, driven by a strategic shift to branded products and major infrastructure expansion.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Sparc Technologies Limited reported a significant net loss of $1.86 million for the half-year ended December 2025, highlighting ongoing financial pressures despite continued R&D efforts. The company flagged material uncertainty over its ability to continue as a going concern.

Mayfield Group Holdings Ltd has reported a striking 52.8% increase in revenue and a 127.6% jump in profit for the half-year ending December 2025, driven by manufacturing growth and strategic acquisitions.

Yowie Group Limited reported a steep 752% increase in its half-year loss to US$4.66 million, amid governance upheaval and impaired loans to its majority shareholder. The company faces ongoing legal and regulatory challenges while pursuing a turnaround.

Terra Metals has raised $85 million through an institutional placement to fast-track exploration and development of its promising Southwest Prospect within the Dante Project in Western Australia.

Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.

Associate Global Partners Limited reported a significantly reduced half-year loss and modest growth in funds under management, underpinned by strong inflows and strategic capital raising.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

HighCom Limited has revealed a sharp downturn in its half-year results, with revenue plunging 59% and a $6.8 million loss after tax, driven by US government shutdown impacts. The company is banking on new lightweight XTclave® armour products to fuel a recovery in the second half of FY26.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Strata Investment Holdings plc reported a striking £6.16 million comprehensive profit for 2025, propelled by robust investment portfolio returns and a significant revaluation uplift in its copper royalty assets. Despite operational delays from adverse weather, the company’s strategic focus on high-conviction resource investments and royalties positions it well amid evolving commodity markets.